Mutated E. coli Enterotoxin A Subunit for Inflammation Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for inflammatory bowel disease (IBD) often come with significant short and long-term side effects, and there is a need for more effective and safer therapies that can reduce inflammation in IBD and other inflammatory conditions.

Innovation Solution

The use of non-toxic A subunits of E. coli heat-labile toxin, specifically the E112K mutant, which inhibits ADP-ribosylation and is combined with a carrier to facilitate internalization into cells, thereby reducing inflammation by inhibiting dendritic cell activation and cytokine secretion.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional anti-inflammatory treatments (NSAIDs, steroidal treatments, immunomodulators) are used to treat IBD, then inflammation is reduced, but significant side effects occur including immune system weakening, pancreatitis, and increased infection risk

Engineering Contradiction:

Improveanti-inflammatory effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent takes the harmful E. coli heat-labile toxin and modifies it by mutating the A subunit to remove its toxic ADP-ribosylation activity while retaining the B subunit's ability to facilitate cellular internalization. This converts a harmful pathogen into a beneficial therapeutic agent that reduces inflammation without the severe side effects of conventional treatments

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The B subunit acts as an intermediary carrier that delivers the mutated A subunit into cells. The B subunit maintains the toxin's ability to bind and internalize into epithelial cells and dendritic cells, while the mutated A subunit provides the anti-inflammatory effect without toxicity, creating a mediator system that achieves therapeutic goals safely

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If NSAIDs are used to treat mild IBD cases, then anti-inflammatory effect is achieved, but the lining of the intestines is damaged worsening symptoms

Engineering Contradiction:

Improveanti-inflammatory effectivenessVSAvoidintestinal lining damage

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful mechanism of intestinal damage into a beneficial therapeutic approach by using a mutated toxin that specifically targets inflammatory pathways without causing the mucosal damage associated with NSAID use

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Speed

If steroidal treatments are used during IBD flare-ups for fast acting anti-inflammatory properties, then inflammation is rapidly reduced, but long term use weakens the immune system

Engineering Contradiction:

Improveanti-inflammatory action speedVSAvoidimmune system weakening

Core Design Contradiction:

SpeedVSObject-affected harmful factors

Solution Approach 1:

The mutated toxin acts as a short-acting therapeutic agent that provides rapid anti-inflammatory effects during flare-ups without the cumulative immune-suppressing effects of long-term steroid use. The agent works locally at the site of action and does not require prolonged systemic exposure

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The E112K mutant composition effectively reduces symptoms of inflammation in IBD and other inflammatory conditions by suppressing inflammatory cytokine release and improving intestinal permeability, with a strong safety profile and minimal side effects.

Implementation Method 1

an E. coli heat labile enterotoxin (LT) non-toxic A subunit which inhibits ADP-ribosylation in a cell pretreated with said non-toxic A subunit when said cell is then contacted with E. coli LT holotoxin

Methodology Applied

Scientific EffectADP-ribosylation inhibition: Enzyme

Implementation Method 2

a carrier which causes internalization of said non-toxic A subunit or non-toxic A1 subunit, or combination thereof, into cells

Methodology Applied

Scientific EffectCellular internalization: Absorption (physical)

Data Source

PatentUS12337025B2Mutated e. coli enterotoxins as anti-inflammatory agents

Publication Date: 2025.06.24 THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND

AI summary

The invention provides compositions and methods for reducing symptoms of inflammation by administering therapeutically effective amounts of (a) (1) enterotoxic E. coli heat labile detoxified toxin A subunit that interferes with the function of ADP-ribosylation factor and inhibits ADP-ribosylation, or (2) A1 subunit that interferes with the function of ADP-ribosylation factor and inhibits ADP-ribosylation, or both (1) and (2), and (b) a carrier that causes internalization of the A subunit or A1 subunit, or both, into cells.